Results 261 to 270 of about 47,972 (292)
Some of the next articles are maybe not open access.
Aspirin Resistance: Does It Exist?
Seminars in Thrombosis and Hemostasis, 2007Aspirin irreversibly inhibits platelet cyclooxygenase-1 (COX-1). Aspirin sensitivity can be measured easily by its inhibition of arachidonic acid (AA) -induced platelet aggregation. Aspirin resistance has to be defined by its inability to inhibit COX-1. By using this definition, aspirin resistance very likely does not exist. A specific rapid laboratory
Rao, Gundu H.R., Michiels, Jan J.
openaire +4 more sources
Aspirin and aspirin resistance in coronary artery disease
Current Opinion in Pharmacology, 2013Aspirin is still the mainstay of antiplatelet therapy in the secondary prevention of coronary artery disease. However certain patients do not benefit from the antithrombotic effects of aspirin. The phenomenon of so-called aspirin resistance can be considered from the clinical and laboratory perspective.
Gregory Y.H. Lip +2 more
openaire +3 more sources
Aspirin resistance: Truth or dare
Pharmacology & Therapeutics, 2006Acetylsalicylic acid, or aspirin (ASA), is widely used in patients with cardiovascular disease to prevent acute ischemic events. However, platelet response to ASA is not equal in all individuals, and a high variability in the prevalence of ASA resistance is reported in the literature (0.4-83%).
Jean G. Diodati +3 more
openaire +3 more sources
The Thoracic and Cardiovascular Surgeon, 2009
Temporary aspirin resistance can occur during the post-CABG period. If the factors causing resistance can be identified, the incidence of early graft occlusions can also be minimized.25 elective CABG cases were enrolled in the study. The platelet count, mean platelet volume, the C-reactive protein level, lipid profile, blood urea nitrogen (BUN), and ...
Sokullu O +7 more
openaire +3 more sources
Temporary aspirin resistance can occur during the post-CABG period. If the factors causing resistance can be identified, the incidence of early graft occlusions can also be minimized.25 elective CABG cases were enrolled in the study. The platelet count, mean platelet volume, the C-reactive protein level, lipid profile, blood urea nitrogen (BUN), and ...
Sokullu O +7 more
openaire +3 more sources
Journal of Stroke Medicine, 2018
Stroke is a leading cause of death and disability worldwide. Aspirin is the most commonly used antiplatelet drug in both primary and secondary prevention of cerebrovascular and cardiovascular diseases. A proportion of patients may have stroke recurrence while they are on treatment with aspirin, giving rise to term aspirin resistance or aspirin failure.
Rohit Bhatia, Pranjal Sisodia
openaire +2 more sources
Stroke is a leading cause of death and disability worldwide. Aspirin is the most commonly used antiplatelet drug in both primary and secondary prevention of cerebrovascular and cardiovascular diseases. A proportion of patients may have stroke recurrence while they are on treatment with aspirin, giving rise to term aspirin resistance or aspirin failure.
Rohit Bhatia, Pranjal Sisodia
openaire +2 more sources
Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward
Ca-A Cancer Journal for Clinicians, 2021Amila K Nanayakkara +2 more
exaly
Evolving standards of care and new challenges in the management of HER2‐positive breast cancer
Ca-A Cancer Journal for Clinicians, 2020Ciara C O’sullivan +2 more
exaly
An update on the immune landscape in lung and head and neck cancers
Ca-A Cancer Journal for Clinicians, 2020Jennifer W Carlisle +2 more
exaly
Diagnostics for Aspirin Resistance
Molecular Diagnosis & Therapy, 2008Udaya S. Tantry +2 more
openaire +3 more sources